1. Introduction {#s0005}
===============

Gaucher disease (GD), common lysosomal storage disease (LSD), is caused by mutations in *GBA1* with resultant defective glucocerebrosidase (GCase) activity and consequent accumulation of its substrate β-glucosylceramide (β-GlcCer) in macrophages and other cell types ([@bb0150]). There are three types of GD based on its primary central nervous system (CNS) involvement: Type 1 does not manifest with early onset primary CNS disease and has previously been described as non-neuropathic. Patients with GD types 2 and 3 have primary CNS impairments. Type 2 features acute neuropathic disease of infancy. Type 3 is marked by chronic neuropathy with highly variable primary CNS onset and involvement. The peripheral manifestations of GD include hepatosplenomegaly and pancytopenia, due to bone marrow infiltration and splenic sequestration. Although *GBA1* mutations are the primary cause of GD, there is broad heterogeneity in clinical manifestations even among patients carrying the same *GBA1* mutations, ranging from very early disease onset to very mild clinical presentations ([@bb0030], [@bb0080]). These diverse variations are not directly attributable to different *GBA1* mutations and may relate to unidentified modifier genes.

PGRN is also known as granulin--epithelin precursor (GEP) ([@bb0345]), proepithelin (PEPI) ([@bb0255], [@bb0235]), acrogranin ([@bb0010]), and GP88/PC-cell derived growth factor (PCDGF) ([@bb0370]). PGRN is a growth factor with multiple functions, including promoting cell proliferation, stimulating wound healing ([@bb0350], [@bb0115]) and regulating immune response ([@bb0090], [@bb0140], [@bb0155], [@bb0215], [@bb0210], [@bb0225], [@bb0315], [@bb0325], [@bb0330]). PGRN is also an anti-inflammatory molecule that directly binds to TNFR, inhibits TNFα/TNFR1 inflammatory signaling ([@bb0210], [@bb0145], [@bb0205], [@bb0295], [@bb0290], [@bb0355], [@bb0265]), and activates the TNFR2 anti-inflammatory pathway ([@bb0365], [@bb0360], [@bb0320], [@bb0190], [@bb0095]). Autoantibodies against PGRN have been detected in sera from patients with colitis, rheumatoid arthritis, and other autoimmune diseases, and these antibodies block PGRN binding to TNFR ([@bb0270], [@bb0285], [@bb0280], [@bb0275]). Insufficiency of PGRN also associates with various types of CNS diseases, including frontotemporal lobe dementia (haploinsufficiency) ([@bb0015], [@bb0060]), Alzheimer disease ([@bb0045]), and Parkinson disease ([@bb0135], [@bb0040]). In addition, intracellular PGRN plays an important role in lysosome biology, and homozygous deficiency of PGRN causes lysosomal storage diseases, including neuronal ceroid lipofuscinosis ([@bb0005], [@bb0260]) and Gaucher-like disease ([@bb0150], [@bb0055], [@bb0160]). Serum levels of PGRN are significantly decreased in GD patients, and *GRN* variants were found to be prevalent in GD patients. PGRN-deficient mice develop a typical GD-like phenotype. Mechanistically, PGRN functions as a chaperone that facilitates the lysosomal delivery of GCase, the defective enzyme in GD ([@bb0150], [@bb0160]). This function of PGRN may be operative with other lysosome enzymes ([@bb0165]). Interestingly, PGRN and a PGRN-derived peptide, Pcgin, ameliorated GD phenotypes in mouse models and fibroblasts obtained from GD patients.

Chitinases (EC 3.2.2.14) are hydrolytic enzymes that break down glycosidic bonds in chitin ([@bb0240]). They belong to 18 glycosyl hydrolase family, an ancient gene family that is widely expressed from prokaryotes to eukaryotes. Chitotriosidase (CHIT1) was the first discovered and characterized mammalian chitinase ([@bb0035]). CHIT1 has been used as a biomarker for lysosomal storage diseases, including GD ([@bb0125], [@bb0305], [@bb0300]) and Niemann Pick diseases ([@bb0305]). CHIT1 protein and enzymatic activity levels decrease with enzyme replacement therapy in GD patients ([@bb0075]). Chitinase-3-like protein 1 (CHI3L1), also called YLK-40 (based on its three N-terminal amino acids: tyrosine (Y), lysine (K), and leucine (L)), is a 40 kDa mammalian glycoprotein. CHI3L1 binds chitin polymers but lacks chitinase activity. CHI3L1 is a pro-inflammatory marker and elevations of CHI3L1 have been found in auto-immune diseases, such as rheumatoid arthritis, pulmonary sarcoidosis ([@bb0070]), psoriasis ([@bb0020]), interstitial lung disease ([@bb0130]), hypertension ([@bb0340]), and various types of cancer ([@bb0085], [@bb0175], [@bb0245], [@bb0310]). CHI3L1 binds to IL-13 receptor α2, and exerts its biological function by activating downstream mitogen-activated protein kinase, protein kinase B/AKT, and Wnt/β-catenin signaling ([@bb0120]). In this study CHI3L1 was identified as a novel downstream molecule that has potential to be employed as a novel biomarker for diagnosing GD and for examining the therapeutic effects of new GD drug(s).

2. Material and Methods {#s0010}
=======================

2.1. Reagents {#s0015}
-------------

Fibroblasts from GD patients with L444P homozygosity were purchased from Coriell Cell Repositories (Camden, NJ) and cells were cultured in DMEM supplemented with 10% FBS. Antibodies against CHI3L1 and GAPDH were purchased from Santa Cruz Biotechnology (Dallas, Texas).

2.2. Gene Expression Analysis {#s0020}
-----------------------------

C57BL/6 WT mice and PGRN KO mice were maintained at NYU Animal Facility in accordance with an Institutional Animal Care and Use Committee approved protocol. Comparative gene array analysis between WT and PGRN KO CD4 + T cells has been described previously ([@bb0225]). Briefly, naïve CD4^+^ T cells were isolated from spleen of WT and PGRN KO mice, and activated using CD3 and CD28 antibody (Ab) over 24 h. RNA was extracted and quantified with NanoDrop ND-1000. RNA integrity was assessed by standard denaturing agarose gel electrophoresis. The Mouse 4 × 44 K Gene Expression Array v2 (Agilent Technology) with about 39,000 + mouse genes and transcripts represented, all with public domain annotations, was employed for genomic profiling. Sample labeling and array hybridization were performed according to the Agilent One-Color Microarray-Based Gene Expression Analysis protocol (Agilent Technology). Agilent Feature Extraction software (version 11.0.1.1) was used to analyze the acquired array images. Quantile normalization and subsequent data processing were performed with using the GeneSpring GX v11.5.1 software (Agilent Technologies). Differentially expressed genes were identified through Fold Change filtering.

2.3. Real-time Quantitative PCR {#s0025}
-------------------------------

Various tissues, including spleen and lung, from WT and PGRN KO mice were dissected and homogenized in TRIzol® reagent. RNA extraction was performed in accordance with the manufacturer\'s recommended protocol. cDNA was synthesized using SuperScript® Reverse Transcriptase (Invitrogen). SYBR® Green PCR Master Mix (Applied Biosystems) was employed in real-time PCR and the reaction was performed with StepOnePlus™ Real-Time PCR Systems (Applied Biosystems). The mRNA levels of target genes were normalized to GAPDH. The following sequence-specific primers were used for the real-time qPCR: 5′- ACGATTTCCATGGA GTCTGG-3′ and 5′- AATCCTTCCCCTGAGATTGG -3′ for mouse CHI3L1, 5′-CCAGCATATG GGCATACCTT-3′ and 5′-CAGACCTCAGTGGCTCCTTC -3′ for mouse CHI3L3, 5′-CAGTGG CTCAAGGACAACAA-3′, 5′-CGTGGAAAAACCGTTGAAGT-3′ mouse CHI3L4. The presence of a single specific PCR product was verified by melting curve analysis and the experiments were repeated three times.

2.4. GD Mouse Model {#s0030}
-------------------

The induction of the GD phenotype in PGRN null mice has been described ([@bb0150], [@bb0160]). Briefly, the GD phenotype was induced in 8 week-old C57B/L6 WT and PGRN KO mice by (intraperitoneal) IP injection of OVA-Alum (Aluminium hydroxide-emulsified Ovalbumin) at Day 1 and Day 15, followed by intranasal challenge of 1% OVA beginning at Day 29 at a frequency of three times per week for four weeks. In rescue experiments, 4 mg/kg recombinant PGRN or Pcgin, or 60 U/kg imiglucerase were IP injected weekly following initiation of intranasal challenge. Spleens, livers, limbs, and lungs were collected at sacrifice.

D409V/- GD mouse is a model generated by disruption of one *Gba1* allele, and point mutation, D409V, on the other allele ([@bb0025]). The D409V GCase is unstable and rapidly degraded ([@bb0200]) and the D409V/- mice develop Gaucher cells at around 8 weeks of age. At 5-weeks-old, D409V/- mice were injected with rPGRN (4 mg/kg/week) for 4 weeks and then sacrificed for examination of CHI3L1 expression from spleen lysate (*n* = 6 per group).

2.5. Isolation of Organelle From Spleen Tissues {#s0035}
-----------------------------------------------

Spleens from WT and PGRN KO mice with OVA challenge were dissected and the cellular organelles were isolated by using a modified protocol of the Lysosome Isolation Kit (Sigma-Aldrich). Briefly, spleen tissues were homogenized in 1 mL 1 × Extraction buffer (provided by the kit) and centrifuged at 1,000 ×* g* for 10 min at 4 °C. The upper lipid layer was removed and the supernatant was transferred to a sterile Eppendorf tube. Another 1 mL Extraction buffer was added to the pellet and the homogenization was repeated. Pellets containing nuclei and cellular debris were discarded and supernatant was centrifuged at 20,000 ×* g* for 20 min at 4 °C. Pellets containing mitochondria, lysosomes, peroxisomes and endoplasmic reticulum were suspended in SDS-loading buffer and submitted for Mass Spectrometry analysis.

2.6. Mass Spectrometry Analysis {#s0040}
-------------------------------

Mass Spectrometry analysis was performed at the proteomic core facility at New York University School of Medicine as described ([@bb0150]). Briefly, protein samples were reduced with DTT at 57 °C for 1 h and alkylated with iodoacetamide at RT in the dark for 45 min. Samples were loaded onto a NuPAGE® 4--12% Bis-Tris Gel 1.0 mm and stained with GelCode Blue Stain Reagent (Thermo Scientific). Excised gel pieces were de-stained and dehydrated with an acetonitrile rinse and further dried in a SpeedVac concentrator for 20 min. Proteins were digested overnight with sequencing grade-modified trypsin (Promega). High resolution full MS spectra were acquired with a resolution of 70,000, an AGC target of 1e6, with a maximum ion time of 120 ms, and the scan range of 300 to 1500 *m*/*z*. Following each full MS twenty data-dependent high resolution HCD MS/MS spectra were acquired. All MS/MS spectra were collected using the following instrument parameters: resolution of 17,000, AGC target of 2e5, maximum ion time of 250 ms, one microscan, 2 m/z isolation window, fixed first mass of 150 m/z, and NCE of 27. MS/MS spectra were searched against a Uniport mouse database using Sequest within Proteome Discoverer.

2.7. SDS-PAGE and Western Blotting {#s0045}
----------------------------------

Protein samples from lyses of WT and PGRN null mouse tissues were separated by SDS-PAGE and transferred to a nylon membrane after electrophoresis. The membrane was probed with the primary antibody overnight at 4 °C and incubated with secondary antibody for 2 h at room temperature. The bands were developed on the film using ECL Prime Western Blotting Detection Reagent (Amersham Pittsburgh, PA).

2.8. Immunohistochemistry {#s0050}
-------------------------

Paraffin-embedded lung sections from WT and PGRN KO mice were de-paraffinized with xylene and hydrated via ethanol gradient. Antigen was retrieved by using 0.1% trypsin in 0.1% CaCl2 at 37 °C for 30 min. Endogenous hydrogen peroxidase was inactivated by incubation with 3% H~2~O~2~ in PBS for 10 min. The slides were blocked with 3% BSA and 20% goat serum for 30 min. Primary antibodies were diluted at 1:20--50 with 2% goat serum and primed on the slides at 4 °C overnight. The next day, slides were washed with PBS and secondary antibody was added (1:200 biotin-labeled goat-anti rabbit antibody or goat-anti mouse antibody) for 1 h. The staining was visualized by Vector ABC peroxidase kit, followed by DAB substrate.

2.9. ELISA Quantification of CHIT1 and CHI31L From Human Sera {#s0055}
-------------------------------------------------------------

Sera from 115 GD patients with N370S mutation in *GBA1*, and 55 healthy controls from Ashkenazi Jews were collected from New York University Medical Center and Mount Beth Israel Medical Center, as reported previously ([@bb0160]). Serum PGRN level was measured as previously described ([@bb0160]). Serum levels of CHIT1 and CHI3L1 were quantified using kits from Aviva Systems Biology (San Diego, CA). Briefly, the ELISA plates were blocked with 300 μl blocking buffer for 30 min. After blocking, buffer was discarded and 100ul of sera, diluted ten-fold in sterile PBS, and appropriate standards were loaded and incubated for 2 h. Plates were washed with PBS 5 times and 100 μl Detection Antibody was added for 1 h. Plates were washed again and 100 μl Detector was added for 1 h. Plates were rinsed and 100 μl TMB Substrate Solution was added and the reaction was terminated by Stop solution. The results were readout at 450 nm using a plate reader. The concentrations of CHIT1 and CHI31L were calculated based on the standard curve.

2.10. Statistical Analyses {#s0060}
--------------------------

Student *t*-tests were used to compare serum levels of PGRN, CHI3L1 and CHIT1 in healthy controls and GD patients. The correlations of PGRN, CHI3L1, and CHIT1 were plotted by linear correlation and the statistical significance were analyzed by Pearson correlation method. For comparison of treatment groups, we performed unpaired t-tests, paired t-tests, and one-way or two-way ANOVA (where appropriate). All statistical analysis was performed using SPSS Software. Statistical significance was two-sided and was achieved when at *p* \< 0.05.

3. Results {#s0065}
==========

3.1. Chitinase-3 Like Family Members Were Up-regulated in PGRN Null Mice {#s0070}
------------------------------------------------------------------------

Previously, we have found that PGRN directly binds to TNFR and is therapeutic against inflammatory arthritis ([@bb0265]). In addition to antagonizing TNFα activity, PGRN potently stimulates T~reg~ population and enhances production of anti-inflammatory cytokine IL-10 ([@bb0090], [@bb0315]). To investigate the molecular mechanisms of PGRN in T cell function, naïve CD4^+^ T cells from WT and PGRN null mice were isolated and activated by CD3 and CD28 antibody treatment. Total RNA was extracted for gene array analysis, as reported previously ([@bb0225]). Approximately 2600 genes were differentially regulated in PGRN null mice as compared to WT mice and about 1200 of these were up-regulated ([@bb0225]). Of these up-regulated genes 350 genes were increased \> 4.5-fold. Chemokine family members, CXCL9 and CXCL10, were dramatically induced ([@bb0225]). Also, Chitinase-3 like family mRNAs were significantly induced in PGRN null CD4^+^ T cells ([Fig. 1](#f0005){ref-type="fig"}A, B); specifically, Chitinase-3-like-3 (CHI3L3) was increased 21.3 fold, Chitinase-3-like 4 (CHI3L4) was increased 8.2 fold, and Chitinase-3-like-1 (CHI3L1) was increased 4.9 fold ([Fig. 1](#f0005){ref-type="fig"}A, B).Fig. 1Chitase-3 like family members were increased in PGRN KO mice. (A) Gene array analysis of gene expression profile of CD4^+^ T cells from WT and PGRN KO mice. Naive CD4^+^ T cells were isolated from spleen of WT and PGRN KO mice, and activated overnight with CD3 and CD28 antibodies. The mRNA was isolated and analyzed using the Mouse Gene Expression Array v2 (Agilent Technology). Genes upregulated \> 4.5 fold were shown. The fold change of Chitase-3 like family members and other cytokines is indicated in Table. (B) Expression of Chitase-3 like family members in various tissues. Liver, spleen, kidney, lung, and brain were dissected from WT and PGRN KO mice. RNA was extracted and expressions of Chitase-3 like family members were determined by quantitative real-time PCR. The expressions were normalized with housekeeping gene GAPDH. Figure is representative of three independent experiments.Fig. 1

To confirm the gene array data and to examine the expressions of Chitase-3 like family members in other tissues, RNA from liver, spleen, kidney, lung, and brain from WT and PGRN KO mice, were assessed quantitatively by real-time PCR for expression of CHI3L1, CHI3L3, and CHI3L4. CHI3L1 mRNA increased \~ 8-fold in spleen of PGRN null vs WT, while in other tissues the level of CHI3L1 was comparable to WT ([Fig. 1](#f0005){ref-type="fig"}B). The CHI3L3 mRNA levels varied between tissues with reduced levels in liver, kidney, and lung of PGRN null mice, but comparable in spleen and slightly increased in brain relative to WT ([Fig. 1](#f0005){ref-type="fig"}B). CHI3L4 was undetectable in liver from PGRN null and WT mice, whereas its levels were increased \~ 10-fold in spleen, and 7-fold in kidney of PGRN null mice. CHI3L4 mRNA had comparable levels in WT and PGRN null in lungs and brains ([Fig. 1](#f0005){ref-type="fig"}B). The gene array and qPCR demonstrated that Chitinase-3 like family members, especially CHI3L1 and CHI3L4, were induced in spleen of PGRN null mice.

3.2. CHI3L1 is Enriched in the Organelles in PGRN Null Mice With GD-like Phenotypes {#s0075}
-----------------------------------------------------------------------------------

In a previous effort to determine the role of PGRN in lung inflammation, we challenged PGRN null mice with Ovalbumin (OVA) and found that PGRN KO mice developed prominent GD-like phenotypes unexpectedly. The OVA-induced inflammation is a stressor that accelerates the development of GD-like phenotypes in adult PGRN KO mice, while aged PGRN KO mice develop GD-like phenotypes spontaneously ([@bb0150], [@bb0160]). Intracellular PGRN was shown to be essential for GCase trafficking to the lysosome ([@bb0150], [@bb0160]). PGRN does not affect GCase protein expression and enzymatic activity in total cell extracts, but is required for delivery of GCase to lysosomes in a HSP70 dependent manner ([@bb0165]). Without PGRN, GCase becomes aggregated in cytoplasm, especially under stress conditions ([@bb0160]). To find other proteins that may be affected by the absence of PGRN, MS analyses of enriched organelles, including lysosome, endoplasmic reticulum and mitochondria from splenic extracts from two WT and two PGRN null mice were conducted after induction of the GD phenotype ([Fig. 2](#f0010){ref-type="fig"}A). Average of (Peptide Spectrum Matches PSM) of each hit was calculated from two WT and two PGRN null mice, respectively. The ratio of average PSM in PGRN null to average PSM in WT mice was calculated, and hits that increased or decreased \> 2-fold were sorted ([Fig. 2](#f0010){ref-type="fig"}B). Seven proteins were identified that had increased in PGRN null organelles, and 23 proteins were decreased in PGRN null organelles. Among the 7 proteins, we found CHI3L1, with highest PSM score, was 2.43-fold higher in PGRN null organelles than it in WT organelles ([Fig. 2](#f0010){ref-type="fig"}B).Fig. 2CHI3L1 was enriched in organelles in PGRN KO mice after OVA challenge. (A) Illustration of method to identify proteins changed in organelles in PGRN KO mice. Briefly, two WT and two PGRN KO mice were challenged with OVA, and spleens were dissected for isolating organelles. The enriched organelles were analyzed by Mass Spectrometry at NYU Core facility. (B) Genes enriched or reduced significantly in PGRN KO organelles. The average PSM of WT is ratio with average PSM of PGRN KO mice, changes increased or decreased more than two-fold were listed as significantly.Fig. 2

3.3. The Expression of CHI3L1 is Elevated in PGRN Null GD Animal Model {#s0080}
----------------------------------------------------------------------

Using two independent non-biased screens targeting the RNA and protein levels respectively, CHI3L1 levels were increased in PGRN null mice, especially after induction of GD phenotype. To confirm the gene array and mass spectrum data, splenic lysates were prepared from WT and PGRN null mice, with or without OVA challenge using 5 mice in each cohort. By western-blot analyses, CHI3L1 was increased following OVA challenge in WT mice, and it was higher in PGRN null mice, both at resting level and after OVA challenge, in particular the latter ([Fig. 3](#f0015){ref-type="fig"}A--B). Given that lung tissue from PGRN null mice showed a typical GD-like phenotype and was full of Gaucher cells ([@bb0160], [@bb0150]), the expression of CHI3L1 in lung tissues was also examined using immunohistochemistry. Interestingly, although CHI3L1 mRNA level remained unchanged in the lungs of PGRN null mice ([Fig. 1](#f0005){ref-type="fig"}B), markedly strong staining of CHI3L1 was observed in typical "giant" Gaucher cells of PGRN null mice after OVA challenge when compared to WT after OVA challenge ([Fig. 3](#f0015){ref-type="fig"}C), suggesting that the elevated CHI3L1 protein level seen in PGRN null GD model may result from altered post-transcriptional regulation, such as increased RNA stability and/or reduced protein degradation.Fig. 3CHI3L1 expression was increased in PGRN KO GD animal model. WT and PGRN KO mice received IP injection of OVA at Day 1 and 15, followed by intranasal challenge of 1% OVA at Day 29 for three times per week for four weeks. Spleen tissues were lysed and the level of CHI3L1 was measured by Western blotting (A) and quantified by Image J (B) and the sections of lung tissues were analyzed by immunohistochemistical staining (C). Lungs were collected from aged-matched WT and *Gba1* D409V/-mice at 4w, 8w, 18w and 28w. RNA were extracted and hybridized with microarray chip as previously reported ([@bb0335]), CHI3L1 expression increased in *Gba1* D409V/-mice (D).Fig. 3

In a separate effort to analyze the developmental global gene expressions in GD, lung tissues from age-matched WT and *Gba1* D409V/null mice at different ages (4 w, 8 w, 18 w, 28 w) were collected for microarray analysis ([@bb0335]). Intriguingly, CHI3L1 expression increased around 5-fold in *Gba1* D409V/null macrophages vs WT at 4 weeks-old, and its levels reached a relative increase of \~ 10-fold in 8-week--old mice. Following the 8 week timepoint, the CHI3L1 level reduced gradually and became a 2-fold increase in adult *Gba1* D409V/null mice (28 week-old) vs WT mice ([Fig. 3](#f0015){ref-type="fig"}D),

3.4. CHI3L1 Expression is Reduced Following Treatment of GD in Animal Models {#s0085}
----------------------------------------------------------------------------

Since PGRN null mice develop a GD phenotype after OVA challenge ([@bb0160]) and CHI3L1 is significantly increased in this GD animal model, we tested whether expression of CHIT3L1 correlated with GD progression. Mice with GD phenotype following OVA challenge and a second group of mice were given injection of Imiglucerase (60 U/kg/week, for four weeks, serving as a positive control). Imiglucerase, modified recombinant GCase used to treat human GD, significantly reduced GD histology, including reduced Gaucher cell number and size ([@bb0160]). Concomitantly, the CHI3L1 level was reduced by imiglucerase treatment ([Fig. 4](#f0020){ref-type="fig"}A).Fig. 4CHI3L1 level was reduced following treatment of GD. (A) Imiglucerase treatment led to reduced level of CHI3L1 in the PGRN KO GD animal model. PGRN KO mice were induced toward a GD phenotype by IP injection of OVA at Day 1 and 15, followed by intranasal challenge of 1% OVA at Day 29 for three times per week for four weeks. One group of mice received imiglucerase (60 μg/kg/week) after Day 29 for four weeks. Lung tissues were collected for immunohistochemistry staining with CHI3L1 specific antibody. (B) PGRN KO mice were induced toward a GD phenotype. Two groups of PGRN KO mice received IP injection of recombinant PGRN protein (4 mg/kg/week) and Pcgin (4 mg/kg/week), respectively, starting after Day 29 for four weeks. Spleen tissues were collected to analyze CHI3L1 expression by western-blot. (C) Quantification of (B) using Image J. (D) Lung tissue sections from PGRN KO mice treated with PGRN or Pcgin from (B) were stained with CHI3L1 specific antibody. (E) Recombinant PGRN injection reduced CHI3L1 expression in *Gba1* D409V/null GD mouse model. 5-weeks-old D409V/null mice were injected with PBS or rPGRN (4 mg/kg/week) for 4 weeks and CHI3L1 expression was measured in spleen lysis. (F) Quantification of (E) by Image J. (G--I) CHI3L1 expressions at both mRNA level (G) and protein level (H) were reduced in the fibroblasts of GD patients following treatment with imiglucerase, PGRN, or Pcgin. Fibroblasts were treated with imiglucerase (160 mU/ml), PGRN (1 μg/ml), and Pcgin (1 μg/ml) for 24 and 48 h respectively. The CHI3L1 mRNA levels were measured by quantitative PCR after 24 h and protein levels were examined by western-blot after 48 h treatment. (I) Quantification of (H) by Image J.Fig. 4

As recombinant PGRN and Pcgin ameliorated GD-like phenotypes in multiple models ([@bb0150], [@bb0160]), PGRN and Pcgin were examined for effects on CHI3L1 expression. PGRN null mice OVA-induced GD phenotype was used. One group of these PGRN null mice received PGRN protein (4 mg/kg/week), and another group mice received Pcgin (4 mg/kg/week). CHI3L1 levels were increased concomitant with the development of the GD phenotype and were found to be significantly reduced in both PGRN- and Pcgin-treated groups as assayed by Western blotting ([Fig. 4](#f0020){ref-type="fig"}B, C) and by immunohistochemical staining ([Fig. 4](#f0020){ref-type="fig"}D). In addition to our PGRN KO GD animal model, we also tested whether PGRN reduced CHI3L1 expression in D409V/- mice. D409V/- develop a GD phenotype spontaneously around 8 weeks of age ([@bb0025]). Recombinant PGRN protein also markedly reduced CHI3L1 expression in spleen tissues of the *Gba1* mutated D409V/null animal model ([Fig. 4](#f0020){ref-type="fig"}E--F).

3.5. CHI3L1 Expression is Reduced Followed Treatment of PGRN and Pcgin in GD Fibroblasts {#s0090}
----------------------------------------------------------------------------------------

CHI3L1 levels were increased in PGRN null GD animal models, and declined following treatment with imiglucerase, PGRN, or Pcgin ([Fig. 4](#f0020){ref-type="fig"}). Next, CHI3L1 expression was assessed in GD patient fibroblasts following treatment with imigluerase, PGRN, or Pcgin. Fibroblasts from GD patients with L444P homozygosity were treated with PGRN (1 μg/ml), Pcgin (1 μg/ml), or Imiglucerase (160 mU/ml) for 24 and 48 h respectively. After 24 h treatment, cells were collected for mRNA analysis. As shown in [Fig. 4](#f0020){ref-type="fig"}G, CHI3L1 mRNA was significantly reduced following treatment with PGRN, Pcgin or Imiglucerase. After 48 h of treatment, cells were collected to compare the CHI3L1 expression at protein level. Similar to the changes at mRNA level, CHI3L1 protein level was also reduced by PGRN, Pcgin, or imiglucerase treatment ([Fig. 4](#f0020){ref-type="fig"}H, I).

3.6. Serum Level of CHI3L1 is Increased in GD Patients {#s0095}
------------------------------------------------------

The findings that increased CHI3L1 expression is associated with PGRN insufficiency and development of a GD-like phenotype and CHI3L1 level is responsive to treatment with FDA-approved drug imiglucerase or with recombinant PGRN or PGRN-derived Pcgin, together with the fact that CHI3L1 belongs to the same chitinase family, as established GD biomarker CHIT1 ([@bb0105]), prompted us to determine whether CHI3L1 can also be employed as a new biomarker for GD patients.

Serum levels of CHIT1, CHI3L1 and PGRN were measured from 121 GD patients and 55 healthy controls of Ashkenazi Jewish descent by ELISA. In line with previous reports, the levels of CHIT1 were significantly higher in GD patients than healthy controls (35.07 ± 2.099 ng/ml in control vs 51.16 ± 2.824 ng/ml in GD, 95% CI: 7.551 to 24.62, *p* \< 0.001) ([Fig. 5](#f0025){ref-type="fig"}A). The level of CHI3L1, similar to CHIT1, was increased in GD patients compared with healthy controls (684.7 ± 68.20 pg/ml in control vs 1736 ± 152.1 pg/ml in GD, 95% CI: 604.9 to 1498, p \< 0.001) ([Fig. 5](#f0025){ref-type="fig"}B). Conversely, the PGRN level was reduced in GD patients, from 150.6 ± 4.501 ng/ml in control to 91.56 ± 3.986 ng/ml in GD, 95 CI: − 72.10 to − 46.05, p \< 0.001 ([Fig. 5](#f0025){ref-type="fig"}C).Fig. 5Serum levels of CHIT1, CHI3L1 and PGRN. Sera from 121 GD patients and 55 healthy controls from Ashknaiz Jewish descent were used to measure CHIT1, CHI3L1 and PGRN level by ELISA kits. Student\'s *t*-test was used to compare the levels of those molecules in healthy controls and GD patients (\*\* stands for *p* \< 0.01).Fig. 5

Analysis of correlations among PGRN, CHI3L1, and CHIT1 in both healthy controls and GD patients, surprisingly revealed that CHI3L1 and PGRN were positively correlated in both healthy controls and GD patients; albeit the correlation in healthy controls (*r* = 0.3261, *P* = 0.0237) was weaker than in GD patients (*r* = 0.357, p \< 0.001) ([Fig. 6](#f0030){ref-type="fig"}A--C). Interestingly, there was no correlation between CHIT1 and PGRN in healthy controls (*r* = 0.223, *p* = 0.1014); however, a strong positive correlation was found in GD patients (*r* = 0.44075, p \< 0.001) ([Fig. 6](#f0030){ref-type="fig"}D--F). Similarly, there was no correlation between CHI3L1 and CHIT1 in healthy controls (*r* = 0.1517, *p* = 0.3031), while a significant positive correlation was found in GD patients (*r* = 0.2081, *p* = 0.025) ([Fig. 6](#f0030){ref-type="fig"}G--I). These results clearly indicate PGRN, CHI3L1 and CHIT1 are functionally closely related, especially in GD patients.Fig. 6Correlation analysis of CHI3L1, PGRN and CHIT1. Serum levels of CHI3L1, PGRN, and CHIT1 were plotted with each other individually by SPSS software, and Pearson correlation were analyzed in healthy controls and GD patients respectively (*p* \< 0.05 is statistical significance) A--C: Correlation between PGRN and CHI3L1; D--F: Correlation between PGRN and CHIT1; and G--I: Correlation between CHIT1 and CHI3L1.Fig. 6

4. Discussion {#s0100}
=============

CHI3L1 is a secreted glycoprotein produced by a variety of cells, including neutrophils, monocytes/macrophages, osteoclasts and other tissues ([@bb0065]). CHI3L1 is able to bind to Chitin, but lacks enzymatic activity to cleave Chitin. CHI3L1 is considered a pro-inflammatory marker, as it stimulates production of inflammatory mediators (e.g., CCL2, CXCL2, MMP-9) ([@bb0195]), and has been reported to be associated with various kinds of autoimmune disorders, including colitis, rheumatoid arthritis, systemic sclerosis, diabetic mellitus, and asthma ([@bb0070]). CHI3L1 is considered a cancer marker as well, since its expression is associated with various types of cancer, including melanoma ([@bb0085]), thyroid carcinoma ([@bb0220]), colorectal cancer ([@bb0250]), and breast cancer ([@bb0050]). Although CHI3L1 has multiple biological functions, the molecular mechanisms by which CHI3L1 is involved in a wide spectrum of diseases are still unclear. Notably, CHI3L1 is a key molecule in the regulation of macrophage function, and CHI3L1 has been implicated in above diseases, at least partially through its regulation of macrophages ([@bb0185], [@bb0170], [@bb0180]).

GD is characterized by accumulation of lipid-engorged macrophages, resulting from GlcCer accumulation as a consequence of reduced enzymatic activity of GCase ([@bb0100], [@bb0110]). A recent study demonstrated that the immune system, in particular complement C5, also plays an important role in the pathogenesis of GD ([@bb0230]). PGRN is a newly identified regulator of GD through direct binding to GCase and facilitating the delivery of GCase to lysosome ([@bb0160]). Deficiency of PGRN led to typical GD phenotypes in mice ([@bb0160]). In addition, *GRN* gene mutations are widely present in GD patients and serum levels of PGRN are significantly reduced in GD patients ([@bb0160]). In a gene array screening from T cells of WT and PGRN KO mice, Chitinase-3 like family members (CHI3L1, CHI3L3, CHI3L4) are up-regulated in PGRN KO mice ([Fig. 1](#f0005){ref-type="fig"}A). CHI3L1 was confirmed to have the strongest induction among the three members, especially in spleen ([Fig. 1](#f0005){ref-type="fig"}B). In a separate effort to identify proteins that are potentially regulated by PGRN during protein intracellular traffic from ER to lysosome, we isolated cellular organelles from WT and PGRN KO mice spleen tissue, followed by mass spectrum analysis ([Fig. 2](#f0010){ref-type="fig"}A). CHI3L1 was identified as the hit most abundantly enriched in PGRN KO mice organelles ([Fig. 2](#f0010){ref-type="fig"}B). Clearly, two unbiased screens led to the identification of CHI3L1 as a downstream molecule that is negatively regulated by PGRN. Whether and how CHI3L1 mediates the function of PGRN, especially in Gaucher disease and other lysosomal storage diseases, warrants further investigation.

PGRN null mice develop a cellular phenotype will hallmarks of GD, and CHI3L1 level is significantly increased in this PGRN null GD animal model ([Fig. 3](#f0015){ref-type="fig"}). In addition, CHI3L1 expression was reduced following treatment with imiglucerase, recombinant PGRN, or PGRN derivative Pcgin in the PGRN null animal model and fibroblasts obtained from GD patients ([Fig. 4](#f0020){ref-type="fig"}), indicating that CHI3L1 level is associated with GD progression. Moreover, CHI3L1 may be a useful biomarker for testing the potential therapeutic effects of newly-developed drug(s) for GD and other lysosomal storage diseases.

We measured serum levels of CHIT1, PGRN, and CHIT3L1 in healthy controls and GD patients. In line with previous reports, serum levels of CHIT1 are significantly higher in GD patients than in healthy controls. Similarly, serum levels of CHI3L1 are also significantly higher ([Fig. 5](#f0025){ref-type="fig"}), while serum levels of PGRN are reduced in GD patients, compared with healthy controls ([Fig. 5](#f0025){ref-type="fig"}). Surprisingly, correlation analysis among these three factors revealed that PGRN levels are positively correlated with CHI3L1 and CHIT1 in GD patients; there is a weaker correlation between PGRN and CHI3L1 in healthy controls, but no correlation between PGRN and CHIT1 in healthy controls. Although CHI3L1 was isolated as an upregulated gene in PGRN KO mice ([Fig. 1](#f0005){ref-type="fig"}, [Fig. 2](#f0010){ref-type="fig"}) and recombinant PGRN negatively regulated CHI3L1 expression in mouse tissues and GD patient fibroblasts ([Fig. 3](#f0015){ref-type="fig"}, [Fig. 4](#f0020){ref-type="fig"}), serum levels of PGRN/CHI3L1 are positively correlated in GD patients. These paradoxical findings may result from: 1) that PGRN may be involved in the regulation of the intracellullar and extracellular distribution of CHI3L1 and 2) that other unknown co-factor(s) may affect the expression and/or secretion of CHI3L1, leading to the intriguing correlation between PGRN and CHI3L1 in tissues and body fluids. In PGRN null GD animal models, we measured the intra-cellular levels of CHI3L1 by qPCR and Western-blot, whereas in human samples we measured the serum, i.e. extracellular CHI3L1. In addition, all the GD patient samples used in this study are from individuals that have received treatment. We have shown that CHI3L1 expression was reduced following treatment, and therefore disease management may also contribute to the paradoxical correlation. Furthermore, CHIT1 is a clinical biomarker currently used for diagnosing GD. Interestingly, CHIT1 is also correlated with PGRN in GD patients, which is similar to the correlation between PGRN/CHI3L1. Therefore, it is conceivable that shared mechanisms may contribute to the intriguing relationship among these three molecules. Further studies are needed to thoroughly elucidate the underlying molecular and cellular mechanisms.

In summary, this study identifies CHI3L1 as a previously-unrecognized molecule associated with GD, thus providing a foundation for future discoveries relating to this interesting factor in GD and other lysosomal storage diseases. We have shown that CHI3L1 is upregulated in PGRN null GD model mice, and its expression is correlated with GD progression in both animal models and patient fibroblasts. In addition, CHI3L1 is correlated with PGRN in GD patients, and more importantly, its serum levels are significantly increased in GD patients, as is similar to a current related clinical biomarker CHIT1. Thus, identification and characterization of this new molecule in GD may lead to innovative diagnostic biochemical approaches for LSDs, in particular GD. Additionally, this factor may be also employed as a biomarker for evaluating the therapeutic effects of new treatments for GD. It is also noted that follow-up studies, including those to address the range of expression in untreated patients over degrees of documented clinical severity, and reductions in this marker with clinical response to therapy, are needed to further validate CHI3L1 as a new biomarker of GD and to determine whether CHI3L1 is a better biomarker than those currently employed, in particular CHIT1.
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